schliessen

Filtern

 

Bibliotheken

Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice

Appropriate adjuvant, proper antigen(s) and a suitable formulation are required to develop stable, safe and immunogenic vaccines. Leishmanial cysteine proteinase type I (CPB) is a promising vaccine candidate; nevertheless, it requires a delivery system to induce a potent immune response. Herein, sol... Full description

Journal Title: Parasite immunology June 2011, Vol.33(6), pp.335-48
Main Author: Doroud, D
Other Authors: Zahedifard, F , Vatanara, A , Najafabadi, A R , Rafati, S
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1365-3024 ; PMID: 21410716 Version:1 ; DOI: 10.1111/j.1365-3024.2011.01289.x
Link: http://pubmed.gov/21410716
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: medline21410716
title: Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice
format: Article
creator:
  • Doroud, D
  • Zahedifard, F
  • Vatanara, A
  • Najafabadi, A R
  • Rafati, S
subjects:
  • Adjuvants, Immunologic -- Administration & Dosage
  • Cysteine Proteases -- Immunology
  • Leishmania Major -- Immunology
  • Leishmaniasis, Cutaneous -- Prevention & Control
  • Liposomes -- Administration & Dosage
  • Nanoparticles -- Administration & Dosage
  • Protozoan Vaccines -- Immunology
ispartof: Parasite immunology, June 2011, Vol.33(6), pp.335-48
description: Appropriate adjuvant, proper antigen(s) and a suitable formulation are required to develop stable, safe and immunogenic vaccines. Leishmanial cysteine proteinase type I (CPB) is a promising vaccine candidate; nevertheless, it requires a delivery system to induce a potent immune response. Herein, solid lipid nanoparticles (SLN) have been applied for CPB [with and without C-terminal extension (CTE)] formulation to utilize as a vaccine against Leishmania major infection in C57BL/6 mice. Therefore, SLN-CPB and SLN-CPB(-CTE) formulations were prepared from cetyl palmitate and cholesterol, using melt emulsification method. After intraperitoneal vaccination and subsequent L. major challenge, a strong antigen-specific T-helper type 1 (Th1) immune response was induced compared to control groups. Lymph node cells from immunized mice displayed lower parasite burden, higher IFN-γ, IgG2a and lower IL-4 production, indicating that robust Th1 immune response had been induced. Our results revealed that CTE is not necessary for inducing protective responses against L. major infection as the IFN-γ/IL-4 ratio was significantly higher, whereas IgG1 responses were lower in the SLN-CPB(-CTE) vaccinated group, post-challenge. Thus, SLN-CPB(-CTE) was shown to induce specific Th1 immune responses to control L. major infection, through effective antigen delivery to the peritoneal antigen presenting cells.
language: eng
source:
identifier: E-ISSN: 1365-3024 ; PMID: 21410716 Version:1 ; DOI: 10.1111/j.1365-3024.2011.01289.x
fulltext: fulltext
issn:
  • 13653024
  • 1365-3024
url: Link


@attributes
ID121206761
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid21410716
sourceidmedline
recordidTN_medline21410716
sourceformatXML
sourcesystemOther
pqid876233550
galeid255910038
display
typearticle
titleCysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice
creatorDoroud, D ; Zahedifard, F ; Vatanara, A ; Najafabadi, A R ; Rafati, S
ispartofParasite immunology, June 2011, Vol.33(6), pp.335-48
identifier
subjectAdjuvants, Immunologic -- Administration & Dosage ; Cysteine Proteases -- Immunology ; Leishmania Major -- Immunology ; Leishmaniasis, Cutaneous -- Prevention & Control ; Liposomes -- Administration & Dosage ; Nanoparticles -- Administration & Dosage ; Protozoan Vaccines -- Immunology
descriptionAppropriate adjuvant, proper antigen(s) and a suitable formulation are required to develop stable, safe and immunogenic vaccines. Leishmanial cysteine proteinase type I (CPB) is a promising vaccine candidate; nevertheless, it requires a delivery system to induce a potent immune response. Herein, solid lipid nanoparticles (SLN) have been applied for CPB [with and without C-terminal extension (CTE)] formulation to utilize as a vaccine against Leishmania major infection in C57BL/6 mice. Therefore, SLN-CPB and SLN-CPB(-CTE) formulations were prepared from cetyl palmitate and cholesterol, using melt emulsification method. After intraperitoneal vaccination and subsequent L. major challenge, a strong antigen-specific T-helper type 1 (Th1) immune response was induced compared to control groups. Lymph node cells from immunized mice displayed lower parasite burden, higher IFN-γ, IgG2a and lower IL-4 production, indicating that robust Th1 immune response had been induced. Our results revealed that CTE is not necessary for inducing protective responses against L. major infection as the IFN-γ/IL-4 ratio was significantly higher, whereas IgG1 responses were lower in the SLN-CPB(-CTE) vaccinated group, post-challenge. Thus, SLN-CPB(-CTE) was shown to induce specific Th1 immune responses to control L. major infection, through effective antigen delivery to the peritoneal antigen presenting cells.
languageeng
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://pubmed.gov/21410716$$EView_this_record_in_MEDLINE/PubMed
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutMedline.html$$EView_the_MEDLINE/PubMed_Copyright_Statement
search
creatorcontrib
0Doroud, D
1Zahedifard, F
2Vatanara, A
3Najafabadi, A R
4Rafati, S
titleCysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice
descriptionAppropriate adjuvant, proper antigen(s) and a suitable formulation are required to develop stable, safe and immunogenic vaccines. Leishmanial cysteine proteinase type I (CPB) is a promising vaccine candidate; nevertheless, it requires a delivery system to induce a potent immune response. Herein, solid lipid nanoparticles (SLN) have been applied for CPB [with and without C-terminal extension (CTE)] formulation to utilize as a vaccine against Leishmania major infection in C57BL/6 mice. Therefore, SLN-CPB and SLN-CPB(-CTE) formulations were prepared from cetyl palmitate and cholesterol, using melt emulsification method. After intraperitoneal vaccination and subsequent L. major challenge, a strong antigen-specific T-helper type 1 (Th1) immune response was induced compared to control groups. Lymph node cells from immunized mice displayed lower parasite burden, higher IFN-γ, IgG2a and lower IL-4 production, indicating that robust Th1 immune response had been induced. Our results revealed that CTE is not necessary for inducing protective responses against L. major infection as the IFN-γ/IL-4 ratio was significantly higher, whereas IgG1 responses were lower in the SLN-CPB(-CTE) vaccinated group, post-challenge. Thus, SLN-CPB(-CTE) was shown to induce specific Th1 immune responses to control L. major infection, through effective antigen delivery to the peritoneal antigen presenting cells.
subject
0Adjuvants, Immunologic -- Administration & Dosage
1Cysteine Proteases -- Immunology
2Leishmania Major -- Immunology
3Leishmaniasis, Cutaneous -- Prevention & Control
4Liposomes -- Administration & Dosage
5Nanoparticles -- Administration & Dosage
6Protozoan Vaccines -- Immunology
general
021410716
1English
2MEDLINE/PubMed (U.S. National Library of Medicine)
310.1111/j.1365-3024.2011.01289.x
4MEDLINE/PubMed (NLM)
sourceidmedline
recordidmedline21410716
issn
013653024
11365-3024
rsrctypearticle
creationdate2011
addtitleParasite immunology
searchscope
0medline
1nlm_medline
2MEDLINE
scope
0medline
1nlm_medline
2MEDLINE
lsr41201106
citationpf 335 vol 33 issue 6
startdate20110601
enddate20110631
lsr30VSR-Enriched:[galeid, pages, pqid, issn]
sort
titleCysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice
authorDoroud, D ; Zahedifard, F ; Vatanara, A ; Najafabadi, A R ; Rafati, S
creationdate20110600
lso0120110600
facets
frbrgroupid3243282460343430195
frbrtype5
newrecords20190701
languageeng
creationdate2011
topic
0Adjuvants, Immunologic–Administration & Dosage
1Cysteine Proteases–Immunology
2Leishmania Major–Immunology
3Leishmaniasis, Cutaneous–Prevention & Control
4Liposomes–Administration & Dosage
5Nanoparticles–Administration & Dosage
6Protozoan Vaccines–Immunology
collectionMEDLINE/PubMed (NLM)
prefilterarticles
rsrctypearticles
creatorcontrib
0Doroud, D
1Zahedifard, F
2Vatanara, A
3Najafabadi, A R
4Rafati, S
jtitleParasite Immunology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Doroud
1Zahedifard
2Vatanara
3Najafabadi
4Rafati
aufirst
0D
1F
2A
3A R
4S
au
0Doroud, D
1Zahedifard, F
2Vatanara, A
3Najafabadi, A R
4Rafati, S
atitleCysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice
jtitleParasite immunology
risdate201106
volume33
issue6
spage335
pages335-348
eissn1365-3024
formatjournal
genrearticle
ristypeJOUR
abstractAppropriate adjuvant, proper antigen(s) and a suitable formulation are required to develop stable, safe and immunogenic vaccines. Leishmanial cysteine proteinase type I (CPB) is a promising vaccine candidate; nevertheless, it requires a delivery system to induce a potent immune response. Herein, solid lipid nanoparticles (SLN) have been applied for CPB [with and without C-terminal extension (CTE)] formulation to utilize as a vaccine against Leishmania major infection in C57BL/6 mice. Therefore, SLN-CPB and SLN-CPB(-CTE) formulations were prepared from cetyl palmitate and cholesterol, using melt emulsification method. After intraperitoneal vaccination and subsequent L. major challenge, a strong antigen-specific T-helper type 1 (Th1) immune response was induced compared to control groups. Lymph node cells from immunized mice displayed lower parasite burden, higher IFN-γ, IgG2a and lower IL-4 production, indicating that robust Th1 immune response had been induced. Our results revealed that CTE is not necessary for inducing protective responses against L. major infection as the IFN-γ/IL-4 ratio was significantly higher, whereas IgG1 responses were lower in the SLN-CPB(-CTE) vaccinated group, post-challenge. Thus, SLN-CPB(-CTE) was shown to induce specific Th1 immune responses to control L. major infection, through effective antigen delivery to the peritoneal antigen presenting cells.
doi10.1111/j.1365-3024.2011.01289.x
pmid21410716
issn01419838
oafree_for_read
date2011-06